DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.05 Bil PE Ratio: 47.26 PB Ratio: 15.58 GF Score: 74/100

Dexcom Inc at Raymond James Institutional Investors Conference (Virtual) Transcript

Mar 01, 2021 / 03:50PM GMT
Release Date Price: R$11.18 (-1.93%)
Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

Okay. Good morning. I think we're live here. My name is Jayson Bedford. I'm the med device analyst here at Raymond James. Thank you for sharing a portion of your day with us here at the 42nd Annual Raymond James Institutional Investors Conference. We're privileged to have with us today the management team from DexCom. Specifically, we have Jereme Sylvain, SVP Finance, Chief Accounting Officer, and Sean Christensen, Head of IR.

So we're going to do a full fireside chat here, and I realize that you guys have covered a lot of topics over the last couple of weeks. But I'd like to cover 3 big topics: G7; awareness, specifically as it relates to the current business; and then maybe new market opportunities.

Questions & Answers

Jayson Tyler Bedford
Raymond James & Associates, Inc., Research Division - Senior Medical Supplies and Devices Analyst

So let's start with G7. You mentioned on the last call that you've completed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot